PRO-POWER is an observational cohort study for a period of 24 weeks. All recruited patients will have essential hypertension. In addition, the patients will have at least one other contributing risk factor for cardiovascular events. The study aims to evaluate the safety, efficacy and protection of Micardis 80mg/Micardis plus 80/12.5mg from cardiovascular risks in patients with essential hypertension
Study Type
OBSERVATIONAL
Enrollment
3,184
Change in Diastolic Blood Pressure From Baseline at Week 24
The change from baseline reflects the week 24 value minus the baseline value.
Time frame: Baseline and Week 24
Change in Systolic Blood Pressure From Baseline at Week 24
The change from baseline reflects the week 24 value minus the baseline value.
Time frame: Baseline and Week 24
Framingham Score at Week 24
The Framingham score represent the cardiovascular risk and ranges from 0 (no risk) to 100% (complete risk).
Time frame: Week 24
Change in the Framingham Score From Baseline at Week 24
The change from baseline reflects the week 24 value minus the baseline value. The Framingham score represent the cardiovascular risk and ranges from 0 (no risk) to 100% (complete risk).
Time frame: Baseline and Week 24
International Renal Interest Society (IRIS) II Score at Week 24
The IRIS II score represent the risk for vascular complication in type to diabetes mellitus and ranges from 0 (no risk) to 100% (complete risk).
Time frame: Week 24
Change in the IRIS II Score From Baseline at Week 24
The change from baseline reflects the week 24 value minus the baseline value. The IRIS II score represent the risk for vascular complication in type to diabetes mellitus and ranges from 0 (no risk) to 100% (complete risk).
Time frame: Baseline and Week 24
Change From Baseline in Urinary Microalbuminuria (Urine Dipstick Test Results)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 28
Al Fayyum, Egypt
Boehringer Ingelheim Investigational Site 18
Alexandria, Egypt
Boehringer Ingelheim Investigational Site 19
Alexandria, Egypt
Boehringer Ingelheim Investigational Site 20
Alexandria, Egypt
Boehringer Ingelheim Investigational Site 21
Alexandria, Egypt
Boehringer Ingelheim Investigational Site 16
Alexandria West, Egypt
Boehringer Ingelheim Investigational Site 17
Alexandria West, Egypt
Boehringer Ingelheim Investigational Site 29
Asyut, Egypt
Boehringer Ingelheim Investigational Site 10
Cairo, Egypt
Boehringer Ingelheim Investigational Site 11
Cairo, Egypt
...and 110 more locations
The change from baseline reflects the shift from baseline in urinary dipstick test results to week 24
Time frame: Baseline and Week 24